<DOC>
	<DOCNO>NCT02985879</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability , pharmacokinetics ABBV-8E12 subject progressive supranuclear palsy ( PSP ) .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety , Tolerability , Pharmacokinetics ABBV-8E12 Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>Male female subject age 40 year great time sign consent . Meets criteria possible probable progressive supranuclear palsy ( SteeleRichardsonOlszewski Syndrome ) . Presence PSP symptoms less 5 year . Subject able walk 5 step minimal assistance ( stabilization one arm use cane/walker ) . Subject identify , reliable , study partner ( e.g. , caregiver , family member , social worker , friend ) . Subjects weigh less 44 kg ( 97 lb ) screening . MMSE score less 15 screening . Any contraindication inability tolerate brain magnetic resonance imaging ( MRI ) . Subject resides skilled nursing dementia care facility , admission facility plan study period . Evidence clinically significant neurological disorder PSP . The subject history currently schizophrenia , schizoaffective disorder bipolar disorder accord DSMV ICD10 criterion . Subject significant illness infection require medical intervention past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>tauopathy</keyword>
	<keyword>PSP</keyword>
	<keyword>Steele-Richardson-Olszewski syndrome</keyword>
</DOC>